Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Benign Prostatic Hyperplasia Treatment Market by Type [Drug (Alpha Blockers(Tamsulosin, Doxazosin), 5-Alpha Reductase Inhibitors (Finasteride, Dutasteride), Surgical Treatment (TURP, TUMT, TUNA], End User (Hospitals) - Global Forecast to 2026

Published by MarketsandMarkets Product code 989928
Published Content info 154 Pages
Delivery time: 1-2 business days
Price
Back to Top
Benign Prostatic Hyperplasia Treatment Market by Type [Drug (Alpha Blockers(Tamsulosin, Doxazosin), 5-Alpha Reductase Inhibitors (Finasteride, Dutasteride), Surgical Treatment (TURP, TUMT, TUNA], End User (Hospitals) - Global Forecast to 2026
Published: February 11, 2021 Content info: 154 Pages
Description

The global benign prostatic hyperplasia treatment market is projected to reach USD 14.1 billion by 2026 from USD 10.8 billion in 2021, at a CAGR of 5.3% from 2021 to 2026. The growth of this market is driven owing to the increasing prevalence of benign prostatic hyperplasia, the rising preference for minimally invasive surgeries, increasing obesity rate, and investments, funds, and grants for research in the field of BPH treatment. Also, the emerging markets and promising product pipeline is anticipated to offer an opportunity for the growth of the market during the forecast period.

"Drug treatment is expected to hold the largest share of the benign prostatic hyperplasia treatment market, by type in 2021."

Based on the type, the BPH treatment market is segmented into drug treatment and surgical treatment. Drug treatment is the largest and the fastest-growing segment in this market. This can primarily be attributed to the use of medications as the first line of treatment among men with mild to moderate symptoms of BPH.

"Home healthcare is expected to hold the largest share of the benign prostatic hyperplasia treatment market, in 2021."

Based on the end user, the market is segmented into home healthcare and hospitals & clinics. In 2019, home healthcare accounted for the largest share of this market, as most patients are prescribed medications over surgery. Patients are also advised to continue taking medications for a few weeks post-surgery and may even require catheters for a few days. As a result, the emphasis in his market is skewed toward home healthcare over hospital care.

"North America commanded the largest share of the benign prostatic hyperplasia treatment market in 2021."

On the basis of region, the benign prostatic hyperplasia treatment market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. In 2019, North America commanded the largest share of the benign prostatic hyperplasia treatment market. The large share of this market segment can be attributed to the rising geriatric and obese population and the availability of research funding are the major factors driving the market growth. Initiatives by key players are also expected to contribute to the market.

Breakdown of supply-side primary interviews, by company type, designation, and region:

  • By Company Type: Tier 1 (20%) , Tier 2 (45%), and Tier 3 (35%)
  • By Designation: C-level (30%), Director-level (20%), and Others (50%)
  • By Region: North America (33%), Europe (24%), AsiaPacific (27%), and Rest of the World (16%)

The some of the major players operating in this market are GlaxoSmithKline plc. (UK), Astellas Pharma Inc. (Japan), Merck & Co., Inc. (US), Eli Lilly and Company (US), and Teleflex Incorporated (US).

List of Companies Profiled in the Report

  • Boston Scientific Corporation (US)
  • Coloplast Group (Denmark)
  • Teleflex Incorporated (US)
  • Olympus Corporation (Japan)
  • GlaxoSmithKline PLC (UK)
  • Eli Lilly (US)
  • Pfizer, Inc. (US)
  • Abbott (US)
  • Asahi Kasei Corporation (Japan)
  • Merck & Co., Inc. (US)
  • Astellas Pharma Inc. (Japan)
  • Allergan plc (Ireland)
  • Alembic (India)
  • IPG Photonics Corporation (US)
  • Richard Wolf GmbH (Germany)
  • Unilab, Inc. (Philippines)
  • Pharex Health Corporation (Philippines)
  • Biolitec AG (Austria)
  • Urologix, LLC (US)
  • Advin Health Care (India)
  • Medifocus, Inc. (Canada)
  • Asclepion Laser Technologies GmbH (Germany)
  • Pnn Medical A/S (Denmark)
  • Surgical Lasers Inc. (Canada)
  • Quanta Systems (Italy)
  • Allium Ltd. (Israel)
  • Lumenis Ltd. (Israel)
  • KARL STORZ SE & Co. KG (Germany)
  • SRS Medical (US).

Research Coverage

This report studies the benign prostatic hyperplasia treatment market based on type, end user and region. The report also analyzes factors (such as drivers, restraints, challenges, and opportunities) affecting market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total benign prostatic hyperplasia treatment market. The report forecasts the revenue of the market segments with respect to four major regions.

Reasons to Buy the Report:

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on benign prostatic hyperplasia treatment offered by the top 29 players in the benign prostatic hyperplasia treatment market. The report analyzes the benign prostatic hyperplasia treatment market type, end user, and region.
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various securement devices across key geographic regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the benign prostatic hyperplasia treatment market
  • Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the benign prostatic hyperplasia treatment market

Frequently asked questions

  • What are the growth opportunities in the benign prostatic hyperplasia treatment market across major regions in the future?
  • Which type of drug is expected to hold the largest share in the benign prostatic hyperplasia treatment market?
  • Which form of surgery has been widely used in BPH treatment?
  • Which region has a well-developed benign prostatic hyperplasia treatment market?
  • What is the impact of COVID-19 on benign prostatic hyperplasia treatment market?
Table of Contents
Product Code: MD 7836

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED FOR THE STUDY
  • 1.4 CURRENCY
  • 1.5 STAKEHOLDERS
  • 1.6 LIMITATIONS OF THE CURRENT EDITION

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 1 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
    • FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
      • 2.1.2.1 Key data from primary sources
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
    • 2.2.1 BOTTOM-UP APPROACH
    • FIGURE 4 BPH TREATMENT MARKET: BOTTOM-UP APPROACH
    • 2.2.2 GROWTH FORECAST
    • 2.2.3 TOP-DOWN APPROACH
    • FIGURE 5 BPH TREATMENT MARKET: TOP-DOWN APPROACH
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 6 DATA TRIANGULATION METHODOLOGY
  • 2.4 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY

    • FIGURE 7 BPH TREATMENT MARKET, BY TYPE, 2021 VS. 2026 (USD BILLION)
    • FIGURE 8 BPH TREATMENT MARKET, BY END USER, 2021 VS. 2026 (USD BILLION)
    • FIGURE 9 BPH TREATMENT MARKET, BY REGION, 2021 VS. 2026 (USD BILLION)

4 PREMIUM INSIGHTS

  • 4.1 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET OVERVIEW
    • FIGURE 10 INCREASING PREVALENCE OF BPH IS THE MAJOR FACTOR DRIVING THE GROWTH OF THIS MARKET
  • 4.2 NORTH AMERICA: BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SHARE, BY TYPE (2020)
    • FIGURE 11 DRUG TREATMENT TO DOMINATE THE NORTH AMERICAN MARKET IN 2020
  • 4.3 GEOGRAPHICAL SNAPSHOT OF THE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET
    • FIGURE 12 JAPAN TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 13 BPH TREATMENT MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing prevalence of benign prostatic hyperplasia
    • FIGURE 14 SHARE OF MALE POPULATION AGED 65 AND ABOVE, GLOBAL (2015-2019)
      • 5.2.1.2 Increasing obesity
      • 5.2.1.3 Rising preference for minimally invasive surgeries
      • 5.2.1.4 Investments, funds, and grants for research in BPH treatment
      • 5.2.1.5 Availability of reimbursement for surgeries
    • TABLE 1 CPT CODES FOR BPH SURGERIES
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Side-effects associated with BPH medications
    • TABLE 2 SIDE-EFFECTS OF BPH DRUGS
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Emerging markets
      • 5.2.3.2 Promising product pipeline
    • TABLE 3 PIPELINE DRUGS
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Low awareness regarding prostate health among men
      • 5.2.4.2 Product recalls in the BPH treatment market
    • TABLE 4 PRODUCT RECALLS IN THE BPH TREATMENT MARKET
  • 5.3 VALUE CHAIN ANALYSIS
    • FIGURE 15 VALUE CHAIN ANALYSIS: MAJOR VALUE IS ADDED DURING THE MANUFACTURING AND ASSEMBLY PHASE
  • 5.4 SUPPLY CHAIN ANALYSIS
    • FIGURE 16 DIRECT DISTRIBUTION-THE PREFERRED STRATEGY OF PROMINENT COMPANIES
  • 5.5 ECOSYSTEM ANALYSIS
    • FIGURE 17 ECOSYSTEM ANALYSIS OF THE PHARMACEUTICAL INDUSTRY
    • FIGURE 18 ECOSYSTEM ANALYSIS OF THE UROLOGY DEVICES MARKET
  • 5.6 REGULATORY SCENARIO
    • 5.6.1 PHARMACEUTICAL INDUSTRY
      • 5.6.1.1 Regulatory requirements
        • 5.6.1.1.1 EU regulations
        • 5.6.1.1.2 US regulations
    • 5.6.2 MEDICAL DEVICES INDUSTRY
    • TABLE 5 LIST OF REGULATORY AUTHORITIES
      • 5.6.2.1 Regulatory requirements
        • 5.6.2.1.1 EU regulations
        • 5.6.2.1.2 US regulations
  • 5.7 AVERAGE SELLING PRICE TREND
    • TABLE 6 AVERAGE SELLING PRICE OF BPH DRUGS
    • TABLE 7 AVERAGE SELLING PRICE OF BPH TREATMENT PROCEDURES
    • TABLE 8 AVERAGE SELLING PRICE OF DEVICES USED IN BPH TREATMENT PROCEDURES
  • 5.8 TECHNOLOGY ANALYSIS
  • 5.9 PESTLE ANALYSIS
  • 5.10 COVID-19 IMPACT ANALYSIS ON THE BPH TREATMENT MARKET
  • 5.11 EPIDEMIOLOGY OF BENIGN PROSTATIC HYPERPLASIA (2019)
    • TABLE 9 BPH: COUNTRY-WISE PREVALENCE, 2019

6 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY TYPE

  • 6.1 INTRODUCTION
    • TABLE 10 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY TYPE, 2018-2026 (USD MILLION)
  • 6.2 DRUG TREATMENT
    • TABLE 11 BPH DRUG TREATMENT MARKET, BY CLASS, 2018-2026 (USD MILLION)
    • TABLE 12 BPH DRUG TREATMENT MARKET, BY REGION, 2018-2026 (USD MILLION)
    • 6.2.1 ALPHA BLOCKERS
    • TABLE 13 BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 14 BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY REGION, 2018-2026 (USD MILLION)
      • 6.2.1.1 Tamsulosin
        • 6.2.1.1.1 Tamsulosin has been prescribed for BPH since 2000
    • TABLE 15 TAMSULOSIN MARKET, BY REGION, 2018-2026 (USD MILLION)
      • 6.2.1.2 Silodosin
        • 6.2.1.2.1 Benefits of silodosin and launch of generics support market growth
    • TABLE 16 SILODOSIN MARKET, BY REGION, 2018-2026 (USD MILLION)
      • 6.2.1.3 Alfuzosin
        • 6.2.1.3.1 Side-effects and fewer generic launches have hindered market growth to some extent
    • TABLE 17 ALFUZOSIN MARKET, BY REGION, 2018-2026 (USD MILLION)
      • 6.2.1.4 Doxazosin
        • 6.2.1.4.1 Doxazosin was introduced in 2005 and has seen many generic launches since
    • TABLE 18 DOXAZOSIN MARKET, BY REGION, 2018-2026 (USD MILLION)
      • 6.2.1.5 Other alpha blockers
    • TABLE 19 OTHER ALPHA BLOCKERS MARKET, BY REGION, 2018-2026 (USD MILLION)
    • 6.2.2 5-ALPHA REDUCTASE INHIBITORS
    • TABLE 20 BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 21 BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY REGION, 2018-2026 (USD MILLION)
      • 6.2.2.1 Dutasteride
        • 6.2.2.1.1 Availability of generics post-patent expiry support market growth
    • TABLE 22 DUTASTERIDE MARKET, BY REGION, 2018-2026 (USD MILLION)
      • 6.2.2.2 Finasteride
        • 6.2.2.2.1 Finasteride provides a range of benefits but is less effective than alpha blockers in improving LUTS
    • TABLE 23 FINASTERIDE MARKET, BY REGION, 2018-2026 (USD MILLION)
    • 6.2.3 OTHER DRUG CLASSES
    • TABLE 24 OTHER BPH DRUG CLASSES MARKET, BY REGION, 2018-2026 (USD MILLION)
  • 6.3 SURGICAL TREATMENT
    • TABLE 25 BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 26 BPH SURGICAL TREATMENT MARKET, BY REGION, 2018-2026 (USD MILLION)
    • 6.3.1 TRANSURETHRAL RESECTION OF THE PROSTATE
      • 6.3.1.1 TURP is the gold standard for BPH treatment
    • TABLE 27 BPH SURGICAL TREATMENT MARKET FOR TURP, BY REGION, 2018-2026 (USD MILLION)
    • 6.3.2 LASER SURGERY
      • 6.3.2.1 Evolution in lasers and high efficacy have supported the demand for laser surgery
    • TABLE 28 BPH SURGICAL TREATMENT MARKET FOR LASER SURGERY, BY REGION, 2018-2026 (USD MILLION)
    • 6.3.3 TRANSURETHRAL MICROWAVE THERMOTHERAPY
      • 6.3.3.1 TUMT has a lower risk of bleeding and requires no hospital stay, which has driven preference
    • TABLE 29 BPH SURGICAL TREATMENT MARKET FOR TUMT, BY REGION, 2018-2026 (USD MILLION)
    • 6.3.4 UROLIFT THERAPY
      • 6.3.4.1 Low rate of post-implantation surgical intervention indicates high effectiveness of UroLift and the potential for adoption
    • TABLE 30 BPH SURGICAL TREATMENT MARKET FOR UROLIFT THERAPY, BY REGION, 2018-2026 (USD MILLION)
    • 6.3.5 TRANSURETHRAL NEEDLE ABLATION OF THE PROSTATE
      • 6.3.5.1 Reimbursement coverage and growing preference for TUNA drive market growth
    • TABLE 31 BPH SURGICAL TREATMENT MARKET FOR TUNA, BY REGION, 2018-2026 (USD MILLION)
    • 6.3.6 REZŪM THERAPY
      • 6.3.6.1 The cost-effectiveness and efficacy of Rezūm water vapor therapy are driving demand for the procedure
    • TABLE 32 BPH SURGICAL TREATMENT MARKET FOR REZŪM THERAPY, BY REGION, 2018-2026 (USD MILLION)
    • 6.3.7 PROSTATIC STENTING
      • 6.3.7.1 Prostatic stenting is a temporary measure conducted under local anesthesia
    • TABLE 33 BPH SURGICAL TREATMENT MARKET FOR PROSTATIC STENTING, BY REGION, 2018-2026 (USD MILLION)
    • 6.3.8 OTHER SURGERIES
    • TABLE 34 OTHER BPH SURGICAL TREATMENTS MARKET, BY REGION, 2018-2026 (USD MILLION)

7 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY END USER

  • 7.1 INTRODUCTION
    • TABLE 35 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY END USER, 2018-2026 (USD MILLION)
  • 7.2 HOME HEALTHCARE
    • 7.2.1 LARGE PATIENT POPULATION USING MEDICATIONS TO DRIVE THE GROWTH OF THE SEGMENT
    • TABLE 36 BPH TREATMENT MARKET FOR HOME HEALTHCARE, BY REGION, 2018-2026 (USD MILLION)
  • 7.3 HOSPITALS & CLINICS
    • 7.3.1 RISING PREFERENCE FOR MINIMALLY INVASIVE SURGERIES TO DRIVE THE GROWTH OF THE SEGMENT
    • TABLE 37 BPH TREATMENT MARKET FOR HOSPITALS & CLINICS, BY REGION, 2018-2026 (USD MILLION)

8 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY REGION

  • 8.1 INTRODUCTION
    • TABLE 38 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY REGION, 2018-2026 (USD MILLION)
  • 8.2 NORTH AMERICA
    • FIGURE 19 NORTH AMERICA: BPH TREATMENT MARKET SNAPSHOT
    • TABLE 39 NORTH AMERICA: BPH TREATMENT MARKET, BY COUNTRY, 2018-2026 (USD MILLION)
    • TABLE 40 NORTH AMERICA: BPH TREATMENT MARKET, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 41 NORTH AMERICA: BPH DRUG TREATMENT MARKET, BY CLASS, 2018-2026 (USD MILLION)
    • TABLE 42 NORTH AMERICA: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018, 2018-2026 (USD MILLION)
    • TABLE 43 NORTH AMERICA: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 44 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 45 NORTH AMERICA: BPH TREATMENT MARKET, BY END USER, 2018-2026 (USD MILLION)
    • 8.2.1 US
      • 8.2.1.1 The US holds the largest share of the North American market
    • TABLE 46 US: BPH TREATMENT MARKET, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 47 US: BPH DRUG TREATMENT MARKET, BY CLASS, 2018-2026 (USD MILLION)
    • TABLE 48 US: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 49 US: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 50 US: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 51 US: BPH TREATMENT MARKET, BY END USER, 2018-2026 (USD MILLION)
    • 8.2.2 CANADA
      • 8.2.2.1 Rising geriatric population and product approvals to support market growth
    • TABLE 52 CANADA: BPH TREATMENT MARKET, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 53 CANADA: BPH DRUG TREATMENT MARKET, BY CLASS, 2018-2026 (USD MILLION)
    • TABLE 54 CANADA: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 55 CANADA: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 56 CANADA: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 57 CANADA: BPH TREATMENT MARKET, BY END USER, 2018-2026 (USD MILLION)
  • 8.3 EUROPE
    • TABLE 58 EUROPE: BPH TREATMENT MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 59 EUROPE: BPH TREATMENT MARKET, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 60 EUROPE: BPH DRUG TREATMENT MARKET, BY CLASS, 2018-2026 (USD MILLION)
    • TABLE 61 EUROPE: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 62 EUROPE: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 63 EUROPE: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 64 EUROPE: BPH TREATMENT MARKET, BY END USER, 2018-2026 (USD MILLION)
    • 8.3.1 GERMANY
      • 8.3.1.1 Increasing healthcare expenditure to support German market growth
    • TABLE 65 GERMANY: BPH TREATMENT MARKET, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 66 GERMANY: BPH DRUG TREATMENT MARKET, BY CLASS, 2018-2026 (USD MILLION)
    • TABLE 67 GERMANY: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018, 2018-2026 (USD MILLION)
    • TABLE 68 GERMANY: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 69 GERMANY: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 70 GERMANY: BPH TREATMENT MARKET, BY END USER, 2018-2026 (USD MILLION)
    • 8.3.2 UK
      • 8.3.2.1 Availability of innovative treatment options to drive the market in the UK
    • TABLE 71 UK: BPH TREATMENT MARKET, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 72 UK: BPH DRUG TREATMENT MARKET, BY CLASS, 2018-2026 (USD MILLION)
    • TABLE 73 UK: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 74 UK: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 75 UK: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 76 UK: BPH TREATMENT MARKET, BY END USER, 2018-2026 (USD MILLION)
    • 8.3.3 FRANCE
      • 8.3.3.1 Rising geriatric population to accelerate the growth of the market
    • TABLE 77 FRANCE: BPH TREATMENT MARKET, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 78 FRANCE: BPH DRUG TREATMENT MARKET, BY CLASS, 2018-2026 (USD MILLION)
    • TABLE 79 FRANCE: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 80 FRANCE: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 81 FRANCE: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 82 FRANCE: BPH TREATMENT MARKET, BY END USER, 2018-2026 (USD MILLION)
    • 8.3.4 REST OF EUROPE
    • TABLE 83 ROE: BPH TREATMENT MARKET, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 84 ROE: BPH DRUG TREATMENT MARKET, BY CLASS, 2018-2026 (USD MILLION)
    • TABLE 85 ROE: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018, 2018-2026 (USD MILLION)
    • TABLE 86 ROE: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 87 ROE: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 88 ROE: BPH TREATMENT MARKET, BY END USER, 2018-2026 (USD MILLION)
  • 8.4 ASIA PACIFIC
    • FIGURE 20 ASIA PACIFIC: BPH TREATMENT MARKET SNAPSHOT
    • TABLE 89 ASIA PACIFIC: BPH TREATMENT MARKET, BY COUNTRY, 2018-2026 (USD MILLION)
    • TABLE 90 ASIA PACIFIC: BPH TREATMENT MARKET, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 91 ASIA PACIFIC: BPH DRUG TREATMENT MARKET, BY CLASS, 2018-2026 (USD MILLION)
    • TABLE 92 ASIA PACIFIC: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018, 2018-2026 (USD MILLION)
    • TABLE 93 ASIA PACIFIC: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 94 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 95 ASIA PACIFIC: BPH TREATMENT MARKET, BY END USER, 2018-2026 (USD MILLION)
    • 8.4.1 JAPAN
      • 8.4.1.1 Japan holds the largest share of the APAC market
    • TABLE 96 JAPAN: BPH TREATMENT MARKET, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 97 JAPAN: BPH DRUG TREATMENT MARKET, BY CLASS, 2018-2026 (USD MILLION)
    • TABLE 98 JAPAN: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018, 2018-2026 (USD MILLION)
    • TABLE 99 JAPAN: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 100 JAPAN: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 101 JAPAN: BPH TREATMENT MARKET, BY END USER, 2018-2026 (USD MILLION)
    • 8.4.2 CHINA
      • 8.4.2.1 Increasing obese population to support market growth
    • TABLE 102 CHINA: BPH TREATMENT MARKET, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 103 CHINA: BPH DRUG TREATMENT MARKET, BY CLASS, 2018-2026 (USD MILLION)
    • TABLE 104 CHINA: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018, 2018-2026 (USD MILLION)
    • TABLE 105 CHINA: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 106 CHINA: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 107 CHINA: BPH TREATMENT MARKET, BY END USER, 2018-2026 (USD MILLION)
    • 8.4.3 INDIA
      • 8.4.3.1 Rising prevalence of obesity to accelerate market growth in India
    • TABLE 108 INDIA: BPH TREATMENT MARKET, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 109 INDIA: BPH DRUG TREATMENT MARKET, BY CLASS, 2018-2026 (USD MILLION)
    • TABLE 110 INDIA: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018, 2018-2026 (USD MILLION)
    • TABLE 111 INDIA: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 112 INDIA: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 113 INDIA: BPH TREATMENT MARKET, BY END USER, 2018-2026 (USD MILLION)
    • 8.4.4 REST OF ASIA PACIFIC
    • TABLE 114 ROAPAC: BPH TREATMENT MARKET, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 115 ROAPAC: BPH DRUG TREATMENT MARKET, BY CLASS, 2018-2026 (USD MILLION)
    • TABLE 116 ROAPAC: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 117 ROAPAC: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 118 ROAPAC: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 119 ROAPAC: BPH TREATMENT MARKET, BY END USER, 2018-2026 (USD MILLION)
  • 8.5 REST OF THE WORLD
    • TABLE 120 ROW: BPH TREATMENT MARKET, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 121 ROW: BPH DRUG TREATMENT MARKET, BY CLASS, 2018-2026 (USD MILLION)
    • TABLE 122 ROW: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018, 2018-2026 (USD MILLION)
    • TABLE 123 ROW: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 124 ROW: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 125 ROW: BPH TREATMENT MARKET, BY END USER, 2018-2026 (USD MILLION)

9 COMPETITIVE LANDSCAPE & COMPANY PROFILES

  • 9.1 COMPETITIVE LANDSCAPE
    • 9.1.1 OVERVIEW
    • FIGURE 21 KEY DEVELOPMENTS IN THE BPH TREATMENT MARKET, JANUARY 2017-JANUARY 2021
    • FIGURE 22 MARKET EVOLUTION FRAMEWORK: JANUARY 2017 TO JANUARY 2021
    • 9.1.2 MARKET SHARE ANALYSIS, 2019
      • 9.1.2.1 BPH Drug Treatment Market Share Analysis, 2019
    • FIGURE 23 BPH DRUG TREATMENT MARKET SHARE ANALYSIS, 2019
      • 9.1.2.2 BPH Surgical Treatment Market Share Analysis, 2019
    • FIGURE 24 BPH SURGICAL TREATMENT MARKET SHARE ANALYSIS, 2019
    • 9.1.3 COMPETITIVE SCENARIO
      • 9.1.3.1 Product launches and approvals
    • TABLE 126 KEY PRODUCT LAUNCHES & APPROVALS, JANUARY 2017-JANUARY 2021
      • 9.1.3.2 Acquisitions
    • TABLE 127 KEY ACQUISITIONS, JANUARY 2017-JANUARY 2021
      • 9.1.3.3 Agreements and collaborations
    • TABLE 128 KEY AGREEMENTS AND COLLABORATIONS, JANUARY 2017-JANUARY 2021
      • 9.1.3.4 Expansions
    • TABLE 129 KEY EXPANSIONS, JANUARY 2017-JANUARY 2021
      • 9.1.3.5 Other developments
    • TABLE 130 OTHER DEVELOPMENTS, JANUARY 2017-JANUARY 2021
    • 9.1.4 COMPANY EVALUATION MATRIX
      • 9.1.4.1 Stars
      • 9.1.4.2 Emerging Leaders
      • 9.1.4.3 Pervasive Companies
      • 9.1.4.4 Participants
    • FIGURE 25 BPH TREATMENT MARKET: COMPANY EVALUATION MATRIX, 2019
    • 9.1.5 COMPETITIVE LEADERSHIP MAPPING (START-UPS AND SMES)
      • 9.1.5.1 Progressive Companies
      • 9.1.5.2 Starting Blocks
      • 9.1.5.3 Responsive Companies
      • 9.1.5.4 Dynamic Companies
    • FIGURE 26 BPH TREATMENT MARKET: VENDOR DIVE MATRIX FOR SMES AND START-UPS, 2019
  • 9.2 COMPANY PROFILES
  • (Business overview, Products offered, Recent Developments, MNM view)**
    • 9.2.1 GLAXOSMITHKLINE
    • FIGURE 27 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2019)
    • 9.2.2 ASTELLAS PHARMA
    • FIGURE 28 ASTELLAS PHARMA INC.: COMPANY SNAPSHOT (2019)
    • 9.2.3 MERCK
    • FIGURE 29 MERCK: COMPANY SNAPSHOT (2019)
    • 9.2.4 ELI LILLY AND COMPANY
    • FIGURE 30 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2019)
    • 9.2.5 TELEFLEX INCORPORATED
    • FIGURE 31 TELEFLEX INCORPORATED: COMPANY SNAPSHOT (2019)
    • 9.2.6 ABBOTT LABORATORIES
    • FIGURE 32 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2019)
    • 9.2.7 BOSTON SCIENTIFIC CORPORATION
    • FIGURE 33 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT (2019)
    • 9.2.8 PFIZER
    • FIGURE 34 PFIZER: COMPANY SNAPSHOT (2019)
    • 9.2.9 OLYMPUS CORPORATION
    • FIGURE 35 OLYMPUS CORPORATION: COMPANY SNAPSHOT (2019)
    • 9.2.10 ALEMBIC
    • FIGURE 36 ALEMBIC: COMPANY SNAPSHOT (2019)
    • 9.2.11 ASAHI KASEI CORPORATION
    • FIGURE 37 ASAHI KASEI CORPORATION: COMPANY SNAPSHOT (2019)
    • 9.2.12 ALLERGAN
    • FIGURE 38 ALLERGAN: COMPANY SNAPSHOT (2019)
    • 9.2.13 COLOPLAST GROUP
    • FIGURE 39 COLOPLAST GROUP: COMPANY SNAPSHOT (2020)
    • 9.2.14 IPG PHOTONICS CORPORATION
    • FIGURE 40 IPG PHOTONICS CORPORATION: COMPANY SNAPSHOT (2019)
    • 9.2.15 KARL STORZ SE & CO. KG
    • 9.2.16 RICHARD WOLF GMBH
    • 9.2.17 LUMENIS LTD.
    • 9.2.18 UNILAB, INC.
    • 9.2.19 PHAREX HEALTH CORP
    • 9.2.20 BIOLITEC AG
    • 9.2.21 UROLOGIX, LLC.
    • 9.2.22 ADVIN HEALTH CARE
    • 9.2.23 MEDIFOCUS INC.
    • 9.2.24 ASCLEPION LASER TECHNOLOGIES GMBH
    • 9.2.25 PNN MEDICAL A/S
    • 9.2.26 SURGICAL LASERS INC.
    • 9.2.27 QUANTA SYSTEM
    • 9.2.28 ALLIUM LTD
    • 9.2.29 SRS MEDICAL
  • *Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.

10 APPENDIX

  • 10.1 INDUSTRY INSIGHTS
  • 10.2 DISCUSSION GUIDE
  • 10.3 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 10.4 AVAILABLE CUSTOMIZATIONS
  • 10.5 RELATED REPORTS
  • 10.6 AUTHOR DETAILS
Back to Top